<DOC>
	<DOCNO>NCT01282970</DOCNO>
	<brief_summary>The objective study investigate safety , tolerability , pharmacokinetics pharmacodynamics BI 135585 XX follow multiple dose administration 14 day</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics Multiple Rising Oral Doses BI 135585 XX Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Inclusion criterion : 1 . Male postmenopausal surgically sterilise female patient establish diagnosis type 2 diabetes mellitus prior inform consent 2 . Antidiabetic treatment diet exercise alone one oral hypoglycaemic drug except glitazones , glucagonlike peptide 1 ( GLP1 ) analogues dipeptidylpeptidase 4 ( DPP4 ) inhibitor . 3 . Antidiabetic treatment unchanged 12 week prior inform consent 4 . Glycosylated haemoglobin A1 ( HbA1c ) ≤ 8.5 % screen 5 . Age ≥ 20 age ≤ 70 year 6 . BMI ≥ 25 BMI ≤ 40 kg/m2 ( Body Mass Index ) 7 . Signed date write informed consent prior admission study accordance GCP local legislation . Exclusion criterion 1 . Any finding medical examination ( include BP , PR ECG ) deviate normal acceptable clinical relevance 2 . Myocardial infarction , stroke transient ischemic attack within 6 month prior inform consent 3 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder besides type 2 diabetes , hyperlipidaemia medically treat hypertension 4 . Gastrointestinal tract surgery might affect absorption elimination drug 5 . Diseases central nerve system ( epilepsy ) psychiatric disorder relevant neurological disorder besides polyneuropathy 6 . Chronic relevant acute infection ( e.g . HIV , hepatitis ) 7 . History allergy/hypersensitivity ( include allergy drug excipients ) deem relevant subject 's safety trial investigator 8 . Intake drug long halflife ( &gt; 24 hour ) within one month prior administration trial drug except allow comedication 9 . Treatment glitazones , GLP1 analogues , insulin , DPP4 inhibitor , systemic inhaled glucocorticoid , antiobesity drug ( e.g . orlistat ) within 12 week prior inform consent 10 . Sensitive CYP3A4 substrate ( e.g . simvastatin , lovastatin , verapamil , budesonide , buspirone , eplerenone , eletriptan , felodipine , fluticasone , midazolam , saquinavir , sildenafil , vardenafil ) CYP3A4 substrates narrow therapeutic range ( e.g . cyclosporine , ergotamine , pimozide , quinidine , sirolimus , tacrolimus , terfenadine ) drug prolong QT/QTc interval ( base knowledge time protocol preparation ) within 10 day prior first administration trial drug 11. exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>